Research with a destination | A question to investigate
A promising ingredient still needs a workable medicine.
A formulation idea becomes interesting when the scientific question meets a practical constraint. We want to explore early research that examines whether a proposed medicine concept can become a reproducible, usable and developable system.
Start with the job the formulation must do.
An early concept might seek a different release profile, improved handling or a more suitable way to deliver an active substance. Each ambition needs a concrete target and a credible comparator. We propose beginning with the intended application, the relevant materials and the conditions the formulation must tolerate. A fashionable platform or ingredient should not decide the research question before the actual development problem has been established with the people who understand it.
Identify the bottleneck before making many variants.
Solubility, physical stability, compatibility, manufacturability and measurement can create different limits. The first collaboration would map which uncertainty is most likely to change the development decision. Existing data may already rule out a route or suggest a narrower experiment. We would distinguish a formulation hypothesis from a claim about clinical performance. Demonstrating a property in an early system does not establish safety, efficacy or suitability for a particular patient population.
Make the comparison practical and interpretable.
A proposed feasibility study would compare a small number of justified candidates with a defined reference under matched conditions. Material identity, preparation steps, storage and analytical methods would be documented. The design should help explain a difference rather than simply discover one. If the available assay cannot distinguish the candidates reliably, improving the measurement may be the most valuable next step before investing in a larger formulation programme or an expensive specialist material.
Look beyond the best laboratory result.
A candidate that performs well once may still be difficult to prepare consistently or maintain over time. We would consider repeated preparation, handling constraints and sensitivity to reasonable process variation at a stage appropriate to the question. The proposed output is an early feasibility assessment with unresolved development risks. It would not be a manufacturing validation package, regulatory submission or promise that the concept can be produced at commercial scale.
A public decision brief | An illustrative example
Open the question.
Inspect the reasoning.
Choose a business question, then look beneath its claim. See what a public source supports, what depends on the local setting and what a useful next step could be.
An academic or development team examining the next experiment after a published model comparison.
What does this result allow us to ask next?
A promising figure can sharpen a research question. Its value depends on keeping the model, observation and next hypothesis distinct.
A proposition to investigate
A clearer question can be a useful output.
An evidence brief could help a team distinguish a published observation from the experiment needed to investigate translation. The proposed value is a more precise comparison and an explicit evidence gap. It does not turn an external model result into a clinical claim or a NEUVIOR discovery.
This is a constructed research-planning question, not an agreed study or product-development result.
What the next brief would contain
A decision someone
can commission.
- The decision
- Whether a specific follow-on question has a credible experimental comparison.
- The comparator
- A scientifically justified model or condition relevant to the proposed hypothesis.
- The evidence
- Full methods, model relevance, measurements, replication and a feasible authorised protocol.
- Stop or redesign
- Stop or redesign if the proposed model cannot answer the question or the required work is not feasible.
Constructed public example | Not PHARMORIS-generated software output or a measured customer result.
Keep this example briefBuild the development path around the evidence.
FDA's process-validation guidance provides manufacturing context, while NPL's good-practice resources provide measurement context (FDA, n.d.; National Physical Laboratory, n.d.). These are reference points for discussing the relevant specialist work; they do not establish compliance or a qualified manufacturing capability. A future programme would need the appropriate formulation expertise, analytical facilities, quality arrangements and regulatory planning. The route should be chosen for the actual product concept and jurisdiction rather than copied from an unrelated successful development story.
Know what is owned and what is only available to study.
A research proposal would identify background knowledge, material access, supplier restrictions and rights to use any resulting data. Collaborators may bring separate intellectual contributions and facilities. Participation would not automatically transfer their rights to NEUVIOR. Commercial interest depends on a usable development route and a plausible need, not merely a novel preparation. We would preserve the distinction between an exploratory formulation concept and a product offered to customers or patients.
Ask for the experiment that changes the decision.
The first step is a bounded feasibility plan around one bottleneck, with inputs, comparator, outputs and stopping criteria agreed before work begins. Continuation might require a reproducible property within a meaningful target range and a credible route to the next study. We would stop or revise the concept if measurement uncertainty overwhelms the difference, instability defeats the intended use or the likely development burden exceeds the value of the proposed application. That is useful progress before scale.
For a candidate that passes the first comparison, the handover should identify the next unresolved property and the evidence required to examine it. That keeps a positive result connected to a development decision, instead of presenting one favourable assay as a complete formulation story.
Sources and context
FDA (n.d.) Process Validation: General Principles and Practices. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/process-validation-general-principles-and-practices (Accessed: 14 October 2026).
National Physical Laboratory (n.d.) Good practice guides. Available at: https://www.npl.co.uk/resources/gpgs (Accessed: 14 October 2026).
Another useful angle.
- Academic and commercial translation
Connect an academic finding with a credible user, comparator and next experiment, while keeping research rights and commercial translation questions clear.
- Cell states and treatment resistance
Explore model-specific questions about changing cell states and treatment resistance, with credible controls, responsible methods and a bounded research proposal.
- Industrial measurement research
Examine whether an industrial measurement can support a medicines process decision, including reference methods, uncertainty, operating conditions and full effort.
